STO-5 PUBLICATIONS & ABSTRACTS
Clinical evidence from STO-5
Evidence / Extended Endocrine / STO-5
STO-5 Trial: 20-yr benefit from Adjuvant Goserelin & Tamoxifen, JCO 2022
Journal of Clinical Oncology, 40:4071-4082 Authors: Johansson et al.
Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
